Cellular and molecular biology of atherosclerotic lesions;Biología celular y molecular de las lesiones ateroscleróticas

Revista Espanola de Cardiologia

Volumn 54, Issue 2, 2001, Pages 218-231

  Martínez Gonzélez, José ^a   Llorente Cortés, Vicente ^a   Badimon, Lina ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

Author keywords

Atherosclerosis; Low density lipoproteins (LDL); Macrophages; Smooth muscle cells (CML)

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ARTERIOSCLEROSIS; GENETICS; HUMAN; INTIMA; MACROPHAGE; MOLECULAR BIOLOGY; MONOCYTE; PATHOLOGY; PHYSIOLOGY; REVIEW; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MOLECULAR BIOLOGY; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; TUNICA INTIMA;

EID: 0037479386     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(01)76294-x     Document Type: Article

References (107)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part I). N Engl J Med 1992; 326: 242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part II). N Engl J Med 1992; 326: 310-318.
3. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-261.
4. Ros R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-808.
5. Badimon L, Chesebro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992; 86 (Supl III): 74-85.
6. Group SSSS. Randomised trial of cholesterol lowering in 4444 patiens with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronany heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 33: 1301-1307.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al, for the Cholesterol and recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
9. The Long-term Intervention with Pravastatin in Patients with Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis prevention Study. JAMA 1998; 279: 1615-1622.
11. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
12. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherosclerosis. Science 1991; 251: 788-791.
13. Pritchard KA Jr, Wong PY, Stemerman MB. Atherogenic concentrations of low-density lipoprotein enhance endothelial cell generation of epoxyeicosatrienoic acid products. Am J Pathol 1990; 136: 1383-1391.
14. Vidal F, Colomé C, Martínez-González J, Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur J Biochem 1998; 252: 378-384.
15. Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510-518.
16. Smalley DM, Lin JHC, Curtis ML, Kobari Y, Stemerman MB, Prichard KA. Native LDL increases endothelial cell adhesiveness by inducing intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 1996; 16: 585-590.
17. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W et al. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992; 89: 6953-6957.
18. Koschinsky T, Bunting CE, Rütter R, Gries FA. Increased growth stimulation of human vascular cells by serum from patients with primary hyper-LDL-cholesterolemia. Atherosclerosis 1987; 63: 7-13.
19. Mata P, Varela O, Lahoz C, Alonso R. de Hoya M, Badimon L. Monounsatured and polyunsatured n-6 fatty acid-enriched diets modify LDL oxidation and decrease human coronary smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol 1997; 17: 2088-2096.
20. Camejo G, Hurt-Camejo E, Olsson U, Böndjers G. Proteoglycans and lipoproteins. Curr Opin Lipidol 1993; 4: 385-391.
21. Camejo G, Hurt E, Romano M. Properties of lipoprotein complexes isolated by affinity chromatography from human aorta. Biochem Biophys Acta 1985; 44: 389-401.
22. Steinberg D, Lewis A. Conner memorial lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-1071.
23. Parhami F, Fang ZF, Fogelman AM, Andalibi A, Territo MC, Berliner JB. MM-LDL induced inflammatory responses in endothelial cells are mediated by cAMP. J Clin Invest 1993; 92: 471-478.
24. Colomé C, Martínez-González J, Vidal F, De Castellarnau C, Badimon L. Small oxidative changes in atherogenic LDL concentrations irreversiblely regulate adhesiveness of human endothelial cells. Effect of the lazaroid U74500A. Atherosclerosis 2000; 149: 295-302.
25. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expresed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-444.
26. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994; 94: 771-778.
27. Navab M, Imes SS, Hama SY. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein I synthesis and is abolish by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046.
28. Vora DK, Fang Z, Parhami F, Fogelman A, Territo M, Berliner J. P-selectin induction by mmLDL and its expression in human atherosclerotic lesons. Circulation 1994; 90: 1-83.
29. Sata M, Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest 1998; 102: 1682-1689.
30. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
31. Kataoka H, Kume N, Miyamoto S, Minami M, Monwaki H, Murase T et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999; 99: 3110-3117.
32. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-1722.
33. Brand K, Eiscle T, Krcusel U, Page M, Page S, Haas M et al. Dysregulation of monocutic nuclear factor-kB by oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17: 1901-1909.
34. Baeuerle PA, Henkel T. Function and activation of NFkB in the immune system. Annu Rev Immunol 1994; 12: 141-179.
35. Thanos D, Maniatis T. NF-kB: a lesson in family values. Cell 1995; 80: 529-532.
36. Bourcier T, Sukhova G, Libby P. The nuclear factor k-B signaling pathway participates in dysiegulation of vascular smooth muscle cells in vitro and in human atherosclerois. J Biol Chem 1997; 272: 15817-15824.
37. Ritchie ME. Nuclear factor-kB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998; 98: 1707-1713.
38. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300: 1142-1147.
39. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans, molecular properties, protein interactions and role in physiological processes. Physiol Rev 1991; 71: 481-539.
40. Vidal F, Colomé C, Martínez-González J, Badimon L. Atherogenic concentrations of native low density lipoproteins modulates niric oxide synthase gene expression in endothelial cells. Eur J Biochem 1998; 252: 374-384.
41. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1601.
42. Ikeda H, Takajo Y, Ichiki K, Ueno T, Maki S, Noda T et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-1696.
43. Frijns CJM, Kappelle LJ, Van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules reflect endothelial cell activation in ische;mic stroke and in carotid atherosclerosis. Stroke 1997; 28: 2214-2218.
44. Nathan C, Xie QW. Nitric oxide synthase: roles, tolls and controls. Cell 1994; 78: 915-918.
45. Varenne O, Pislaru S, Gillijns H, Pelt NV, Gerard RD, Zoldhelyi P et al. Local adenovirus-mediated transfer of endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998; 98: 919-926.
46. 198 (Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-1520.
47. -786 → C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-2870.
48. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90; 649-652.
49. Chen CH, Henry PD. Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression. Proc Assoc Am Physicians 1997; 109: 351-361.
50. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions. Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108-2116.
51. Goligorsky MS, Budzikowski AS, Tsukahara h, Noiri E. Co-operation between endothelium and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999; 26: 269-271.
52. Herbert JM, Dupuy E, Laplace MC, Zini J-M, Bar-Shavit R, Toberlem G. Thrombin induces endothelial cell growth via both a proteolitic and a non-proteolitic pathway. Biochem J 1994; 303: 227-231.
53. Duhamel-Clérin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vas Biol 1997; 17: 1931-1938.
54. Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C. IFN-γ potenciates atherosclerosis in apoE Knock-out mice. J Clin Invest 1997; 99: 2752-2761.
55. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glasgov S, Insull W et al. A definition of advances types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the committee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
56. 2 only aggregation, of low density lipoprotein (LDL) particles. J Biol Chem 1998; 44: 29127-29134.
57. Maor I, Aviram M. Macrophage released proteoglycans are involved in cell-mediated aggregation of LDL. Atherosclerosis 1999; 142: 57-66.
58. Heinecke JW, Suits A, Aviram M, Chait A. Phagocytosis of lipase agreggated low density lipoprotein promotes macrophage foam cell formation: sequencial morphological and biochemical events. Arterioscler Thromb 1991; 11: 1643-1651.
59. Vijayagopal P, Glancy L. Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Arterioscler Thromb Vasc Biol 1996; 16: 1112-1121.
60. Freeman MW. Macrophage scavenger receptors. Curr Opin Lipid 1994; 5: 143-148.
61. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A et al. Modification of low density lipoprotein by advances glycation end products contributes to the dyslipidemia of diabetes and renal insuficiency. Proc Natl Acad Sci USA 1994; 91: 9441-9445.
62. Timo PH, Luoma JS, Nikkari T, Ylä-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lessions. Circulation 1998; 97: 1079-1086.
63. Luoma J, Hiltunen T, Särkioja T, Moestrup SK, Gliemann J, Kodama T et al. Expression of α2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest 1994; 93: 2014-2021.
64. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 4-11.
65. Shah PK, Falk E, Badimon JJ, Fernández-Ortiz A, Mailhac A, Villareal-Levy G et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
66. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronay events. Am J Cardiol 1995; 76: 24C-33C.
67. Rajavashisth TB, Xu XP, Jovinge S, Maisel S, Xu XO, Chai NN et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Circulation 1999; 99: 3103-3109.
68. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433-2444.
69. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-2064.
70. Alfon J, Guasch JF, Berrozpe M, Badimon L. NOS II gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 1999; 145: 325-331.
71. Alfon J, Palazón CP, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 1999; 81: 822-827.
72. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 1044-1048.
73. Wissler RW, Vesselinovitch D, Komatsu A. The contribution of studies of atherosclerotic lesions in young people to future research. Ann NY Acad Sci 1990; 598: 418-434.
74. Ip JH, Fuster V, Badimon L, Badimon JJ, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687.
75. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990; 87: 4600-4604.
76. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemostasis 1995; 74: 552-559.
77. Schneider Dj, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ et al. Changes in arterial expresion of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17: 3294-3301.
78. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180-3191.
79. Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 1996; 78: 44-49.
80. Nabel EG, Liptay S, Yang ZY, Liptay S, San H, Gordon D et al. r-PDGF gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993; 91: 1822-1829.
81. Ferns AA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-1132.
82. Walz DA, Anderson GF, Ciaglowski RE, Aiken M, Fenton II JW. Thrombin-elicited contractile responses of aortic smooth muscle. Proc Soc Exp Biol Med 1985; 180: 518-526.
83. Varela O, Martínez-González J, Badimon L. The response of smooth muscle cells to a-thrombin depends on its arterial origin: comparison among different species. Eur J Clin Invest 1998; 28: 313-323.
84. Meyer BJ, Badimon JJ, Mailhac A, Fernández-Ortiz A, Chesebro JH, Fuster V et al. Inhibition of growth of thrombus on fresh mural thrombus: targeting optimal therapy. Circulation 1994; 90: 2432-2438.
85. Nelken NA, Soiler J, O'Keefe J, Vu TK, Charo I, Coughlin S. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-1622.
86. Noda H, Fuji S, Sobel B. Induction of vascular SMC expression of PAI-1 by thrombin. Circ Res 1993; 72: 36-43.
87. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB et al. Direct gene transfer of TGF-β1 inthearterial wall stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-10764.
88. Martínez-González J, Viñals M, Vidal F, Llorente-Cortes V, Badimon L. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 1997; 135: 213-223.
89. Viñals M, Martínez-González J, Badimon JJ, Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxynase-2 (Cox-2). Arterioscler Thromb Vasc Biol 1997; 17: 3481-3488.
90. Patel MK, Lymn JS, Clunn GF, Hughes AD. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2107-2114.
91. Brown KE, Kindy MS, Sonenshein GE. Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells. J Biol Chem 1992; 267: 4625-4630.
92. Badimon L, Alfon J, Royo T, Berrozpe M, Martínez-González J, Vidal F et al. Cell biology of restenosis post-angioplasty. Z Kardiol 1995; 84: 145-149.
93. Castello A, Cases C, Martínez-González J, Badimon L. A nuclear hormone receptor gene is up-regulated by thrombin in smooth muscle cells. Eur Heart J 1999; 30: 357.
94. Ohkura N, Hijikuro M, Miki K. Antisense oligonucleotide to NOR-1, a novel orphan nuclear receptor, induces migration and neunte extension of cultured forebrain cells. Mol Brain Res 1996; 35: 309-313.
95. Cheng LE, Chan FK, Cado D, Winoto A. Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J 1997; 16: 1865-1875.
96. Van deer Gee P, Hunter T. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251-337.
97. Davis R. The mitogenic-activated protein kinase signal transduction pathway. J Biol Chem 1993; 268: 14553-14556.
98. Bogoyevitch MA. Signalling via stress-activated mitogen-activated protein kinases in the cardiovascular system. Caidiovasc Res 2000; 45: S26-842.
99. Tertov VV, Orckhov AN, Sobenin ZA, Gabbasov A, Popov EG, Yaroslavov AA et al. Three types of naturally ocurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res 1992; 71: 218-228.
100. Tabas I, Yueqing L, Brocia RW, Wen Xu S, Swenson TL, Williams KJ. Lipoprotein lipase and sphingomyelinase sinergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. J Biol Chem 1993; 268: 20-19-20432.
101. Inaba T, Gotoda T, Shimano H, Shimada M, Harda K, Kozaki K et al. Platelet-derived growth factor induces c-fins and scavenger receptor genes in vascular smooth muscle cells. J Biol Chem 1992; 267: 13107-13112.
102. Llorente-Cortés V, Martínez-González J, Badimon L. Low density lipoprotein receptor-related protein mediates the uptake of aggregated low density lipoprotein in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000 (en prensa).
103. Llorente-Cortés V, Martínez-González J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol 1998; 18: 738-746.
104. Herz J, Kowal RC, Goldslein JL, Brown MS. Proteolytic processing of the 600 Kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. EMBO J 1988; 9: 1769-1776.
105. Guyton JR, Klemp KF, Mims MP. Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. J Lipid Res 1991; 32: 953-961.
106. Tamminen M, Mottino G, Qiao JH, Breslow JL, Frank JS. Ultrastructure of early lipid accumulation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 847-853.
107. Berrozpe M, Llorente V, Badimon L. Expression of low density lipoprotein receptor-related protein in human coronary atherosclerotic plaques. Kardiovasckuläre Medizin 1999; 2: 75.